Influence of the glycocalyx and plasma membrane composition on amphiphilic gold nanoparticle association with erythrocytes.

Erythrocytes are attractive as potential cell-based drug carriers because of their abundance and long lifespan in vivo. Existing methods for loading drug cargos into erythrocytes include hypotonic treatments, electroporation, and covalent attachment onto the membrane, all of which require ex vivo manipulation. Here, we characterized the properties of amphiphilic gold nanoparticles (amph-AuNPs), comprised of a ∼2.3 nm gold core and an amphiphilic ligand shell, which are able to embed spontaneously within erythrocyte membranes and might provide a means to load drugs into red blood cells (RBCs) directly in vivo. Particle interaction with RBC membranes occurred rapidly at physiological temperature. We further show that amph-AuNP uptake by RBCs was limited by the glycocalyx and was particularly influenced by sialic acids on cell surface proteoglycans. Using a reductionist model membrane system with synthetic lipid vesicles, we confirmed the importance of membrane fluidity and the glycocalyx in regulating amph-AuNP/membrane interactions. These results thus provide evidence for the interaction of amph-AuNPs with erythrocyte membranes and identify key membrane components that govern this interaction, providing a framework for the development of amph-AuNP-carrying erythrocyte 'pharmacytes' in vivo.

[1]  Sung Tae Kim,et al.  Gold nanoparticles for nucleic acid delivery. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  Prabhani U. Atukorale,et al.  Effect of particle diameter and surface composition on the spontaneous fusion of monolayer-protected gold nanoparticles with lipid bilayers. , 2013, Nano letters.

[3]  M. Maccarini,et al.  Effect of functionalized gold nanoparticles on floating lipid bilayers. , 2013, Langmuir : the ACS journal of surfaces and colloids.

[4]  N. Malmstadt,et al.  Deformation and poration of lipid bilayer membranes by cationic nanoparticles , 2013 .

[5]  F. Stellacci,et al.  Erythrocyte incubation as a method for free-dye presence determination in fluorescently labeled nanoparticles. , 2013, Molecular pharmaceutics.

[6]  Fan Zhan,et al.  Smart photothermal-triggered bilayer phase transition in AuNPs-liposomes to release drug. , 2013, Langmuir : the ACS journal of surfaces and colloids.

[7]  Deepak N. Kapoor,et al.  Characterization and evaluation , 2013 .

[8]  B. Korgel,et al.  Chloroform-enhanced incorporation of hydrophobic gold nanocrystals into dioleoylphosphatidylcholine (DOPC) vesicle membranes. , 2012, Langmuir : the ACS journal of surfaces and colloids.

[9]  Erik C. Dreaden,et al.  The Golden Age: Gold Nanoparticles for Biomedicine , 2012 .

[10]  F. Stellacci,et al.  Dynamic Cellular Uptake of Mixed-Monolayer Protected Nanoparticles , 2012, Biointerphases.

[11]  D. Irvine,et al.  Oligonucleotide delivery by cell-penetrating "striped" nanoparticles. , 2011, Angewandte Chemie.

[12]  H. Azzazy,et al.  Gold Nanoparticles in Biomedicine , 2011 .

[13]  S. Singh,et al.  Functionalized Gold Nanoparticles and Their Biomedical Applications , 2011, Nanomaterials.

[14]  Brahim Lounis,et al.  Direct investigation of intracellular presence of gold nanoparticles via photothermal heterodyne imaging. , 2011, ACS nano.

[15]  I. Bernhardt,et al.  Red Cell Membrane Transport in Health and Disease , 2010 .

[16]  Jordi Arbiol,et al.  Hydrophobic gold nanoparticle self-assembly with phosphatidylcholine lipid: membrane-loaded and janus vesicles. , 2010, Nano letters.

[17]  Chad A. Mirkin,et al.  Gold nanoparticles for biology and medicine. , 2010, Angewandte Chemie.

[18]  P. Vekilov,et al.  Interactions of hemin with model erythrocyte membranes. , 2010, The journal of physical chemistry. B.

[19]  Francesco Stellacci,et al.  Effect of surface properties on nanoparticle-cell interactions. , 2010, Small.

[20]  Martin Lenz,et al.  ATP-dependent mechanics of red blood cells , 2009, Proceedings of the National Academy of Sciences.

[21]  N. Mohandas,et al.  Red cell membrane: past, present, and future. , 2008, Blood.

[22]  Francesco Stellacci,et al.  Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. , 2008, Nature materials.

[23]  Kristen N. Duthie,et al.  Wide varieties of cationic nanoparticles induce defects in supported lipid bilayers. , 2008, Nano letters.

[24]  M. Magnani,et al.  Cell-based drug delivery. , 2008, Advanced drug delivery reviews.

[25]  Francesco Stellacci,et al.  Water-soluble amphiphilic gold nanoparticles with structured ligand shells. , 2008, Chemical communications.

[26]  Seungpyo Hong,et al.  Nanoparticle interaction with biological membranes: does nanotechnology present a Janus face? , 2007, Accounts of chemical research.

[27]  Mehrdad Hamidi,et al.  Applications of carrier erythrocytes in delivery of biopharmaceuticals. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[28]  Vladimir R Muzykantov,et al.  The Glycocalyx Protects Erythrocyte-Bound Tissue-Type Plasminogen Activator from Enzymatic Inhibition , 2007, Journal of Pharmacology and Experimental Therapeutics.

[29]  Sung-Hee Park,et al.  Loading of gold nanoparticles inside the DPPC bilayers of liposome and their effects on membrane fluidities. , 2006, Colloids and surfaces. B, Biointerfaces.

[30]  A. Andriulli,et al.  Erythrocytes-Mediated Delivery of Dexamethasone in Steroid-Dependent IBD Patients—A Pilot Uncontrolled Study , 2005, The American Journal of Gastroenterology.

[31]  Sarah L Veatch,et al.  Miscibility phase diagrams of giant vesicles containing sphingomyelin. , 2005, Physical review letters.

[32]  N. Mohandas,et al.  Modulation of Erythrocyte Membrane Mechanical Function by Protein 4.1 Phosphorylation* , 2005, Journal of Biological Chemistry.

[33]  D. Holdstock Past, present--and future? , 2005, Medicine, conflict, and survival.

[34]  Gianluca Damonte,et al.  Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients. , 2004, Blood cells, molecules & diseases.

[35]  A. Palamara,et al.  Erythrocytes as carriers of reduced glutathione (GSH) in the treatment of retroviral infections. , 2003, The Journal of antimicrobial chemotherapy.

[36]  M. Magnani,et al.  Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL. , 2003, Vaccine.

[37]  T. Triglia,et al.  Erythrocyte-binding antigen 175 mediates invasion in Plasmodium falciparum utilizing sialic acid-dependent and -independent pathways , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. Magnani,et al.  Macrophage protection by addition of glutathione (GSH)-loaded erythrocytes to AZT and DDI in a murine AIDS model. , 2002, Antiviral research.

[39]  Laura Chiarantini,et al.  Erythrocytes deliver Tat to interferon‐γ‐treated human dendritic cells for efficient initiation of specific type 1 immune responses in vitro , 2002, Journal of leukocyte biology.

[40]  M. Hamidi,et al.  Inhibition of serum angiotensin‐converting enzyme in rabbits after intravenous administration of enalaprilat‐loaded intact erythrocytes , 2001, The Journal of pharmacy and pharmacology.

[41]  M. Magnani,et al.  Erythrocyte-mediated delivery of a new homodinucleotide active against human immunodeficiency virus and herpes simplex virus. , 2001, The Journal of antimicrobial chemotherapy.

[42]  L Bigi,et al.  Erythrocyte‐mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease , 2001, Biotechnology and applied biochemistry.

[43]  M. Magnani,et al.  New drug combinations for the treatment of murine AIDS and macrophage protection , 2001, European journal of clinical investigation.

[44]  M. Rouini,et al.  In Vitro Characterization of Human Intact Erythrocytes Loaded by Enalaprilat , 2001, Drug delivery.

[45]  Deborah A. Brown,et al.  Structure and Function of Sphingolipid- and Cholesterol-rich Membrane Rafts* , 2000, The Journal of Biological Chemistry.

[46]  H. Tajerzadeh,et al.  Evaluation of Hypotonic Preswelling Method for Encapsulation of Enalaprilat in Intact Human Erythrocytes , 2000, Drug development and industrial pharmacy.

[47]  A. De Flora,et al.  Heterodimer-loaded erythrocytes as bioreactors for slow delivery of the antiviral drug azidothymidine and the antimycobacterial drug ethambutol. , 1999, AIDS research and human retroviruses.

[48]  P. Somerharju,et al.  Phospholipid composition of the mammalian red cell membrane can be rationalized by a superlattice model. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[49]  S. Grimaldi,et al.  Red blood cells mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to primary macrophages: efficiency metabolism and activity against human immunodeficiency virus or herpes simplex virus. , 1997, Antiviral research.

[50]  M. Bendinelli,et al.  FIV infection of macrophages: in vitro and in vivo inhibition by dideoxycytidine 5'-triphosphate. , 1995, Veterinary immunology and immunopathology.

[51]  Mathias Brust,et al.  Synthesis of thiol-derivatised gold nanoparticles in a two-phase liquid-liquid system , 1994 .

[52]  E. Evans,et al.  Mechanical properties of the red cell membrane in relation to molecular structure and genetic defects. , 1994, Annual review of biophysics and biomolecular structure.

[53]  Felix Franks,et al.  In-Vitro Characterization of mCerulean3_mRuby3 as a Novel FRET Pair with Favorable Bleed-Through Characteristics , 2019, Biosensors.

[54]  N. Jain,et al.  Erythrocytes as carriers of primaquine-preparation: characterization and evaluation , 1992 .

[55]  N. Jain,et al.  Erythrocytes as carriers of metronidazole: In-vitro characterization , 1992 .

[56]  Mitchel Dh,et al.  Bioactivity of electric field-pulsed human recombinant interleukin-2 and its encapsulation into erythrocyte carriers. , 1990 .

[57]  DH Mitchell,et al.  Bioactivity of electric field‐pulsed human recombinant interleukin‐2 and its encapsulation into erythrocyte carriers , 1990, Biotechnology and applied biochemistry.

[58]  G. Ihler,et al.  Hypotonic hemolysis methods for entrapment of agents in resealed erythrocytes. , 1987, Methods in enzymology.

[59]  J. Berman,et al.  Antileishmanial activity of human red blood cells containing formycin A. , 1985, The Journal of infectious diseases.

[60]  D. Lewis,et al.  Therapeutic efficacy of asparaginase encapsulated in intact erythrocytes. , 1985, Biochemical pharmacology.

[61]  H. Eichler,et al.  Release of vitamin B12 from carrier erythrocytes in vitro , 1985, Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie.

[62]  D. Lewis,et al.  Encapsulation of drugs in intact erythrocytes: an intravenous delivery system. , 1983, Biochemical pharmacology.

[63]  D. Lewis,et al.  The use of corticosteroids encapsulated in erythrocytes in the treatment of adjuvant induced arthritis in the rat. , 1983, Biochemical pharmacology.

[64]  J. Deloach,et al.  Circulating carrier erythrocytes: slow-release vehicle for an antileukemic drug, cytosine arabinoside. , 1982, American journal of veterinary research.

[65]  T. Tsong,et al.  Survival of sucrose-loaded erythrocytes in the circulation , 1978, Nature.

[66]  E. Lightfoot,et al.  Asparaginase entrapped in red blood cells: action and survival. , 1976, Science.

[67]  U. Zimmermann,et al.  Enzyme loading of electrically homogeneous human red blood cell ghosts prepared by dielelctric breakdown. , 1976, Biochimica et biophysica acta.

[68]  A. Lowenthal,et al.  Use of enzyme-loaded erythrocytes in in-vitro correction of arginase-deficient erythrocytes in familial hyperargininemia. , 1976, Clinical chemistry.

[69]  H. Hönigsmann,et al.  Glycocalyx of epidermal cells in vitro: demonstration and enzymatic removal. , 1975, The Journal of investigative dermatology.

[70]  R H Glew,et al.  Enzyme loading of erythrocytes. , 1973, Proceedings of the National Academy of Sciences of the United States of America.